Peripapillary hyperreflective ovoid mass-like structures in multiple sclerosis are associated with disease progression
ECTRIMS Online Library. Petzold A. Oct 12, 2018; 232046; 293
Axel Petzold
Axel Petzold
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Discussion Forum (0)
Rate & Comment (0)

Abstract: 293

Type: Scientific Session

Abstract Category: Clinical aspects of MS - Neuro-ophthalmology

Introduction: Peripapillary hyperreflective ovoid mass-like structures (PHOMS) are a new spectral domain optical coherence tomography (OCT) finding and understood to be the consequence of axoplasmic stasis.
Objective: First, to describe the prevalence of PHOMS in patients suffering from multiple sclerosis (MS) and healthy control subjects (HC). Second, to investigate the clinical relevance of PHOMS in MS.
Methods: A prospective, longitudinal study including 212 patients with MS (n=418 eyes) and 59 HC (n=117 eyes). The disability (EDSS) and disease course (relapsing remitting (RRMS), secondary progressive (SPMS) and primary progressive (PPMS) were recorded. Quality controlled (OSCAR-IB) review of OCT ring scans and volume scans for PHOMS. Exclusion of typical optic disc drusen (ODD).
Results: Two of the 271 subjects had typical ODD (one MS, one HC). There were no PHOMS in HC. Therefore compared to HC the prevalence of PHOMS was significantly higher in MS patients (n=34, p=0.001) and MS eyes (n=45, p=0.0002). The highest prevalence of PHOMS was found in PPMS (26%) followed by RRMS (8%) and SPMS (2%). There was no relationship of PHOMS with age or disease duration, but RRMS patients with PHOMS showed more progression on the EDSS over the following 2 years compared to those without PHOMS (p=0.03).
Conclusion: These data suggest that PHOMS are a novel OCT finding in MS, potentially indicating impaired axoplasmatic flow at the optic disc, which may be of potential prognostic relevance.
Disclosure: Dr Petzold reports personal fees from Novartis, grants from Novartis, outside the submitted work; and is part of the steering committee of the OCTiMS study which is sponsored by Novartis and the VUmc received research support. The research was supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology.
D. Coric: nothing to disclose.
BMJU: has received personal compensation for consulting from Biogen Idec, Genzyme, Merck Serono, Novartis, Roche and TEVA.
Prof BMJ Uitdehaag received consultancy fees from Biogen Idec, Genzyme, Merck Serono, Novartis, Roche and Teva.
Dr Balk: the VUmc MS Center received research support for OCT projects from TEVA.

Code of conduct/disclaimer available in General Terms & Conditions
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.

Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.

Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.

Save Settings